Johnson & Johnson to acquire Momenta Pharmaceuticals for $6.5B
August 19, 2020 at 12:56 PM EDT
The real value for Johnson & Johnson is Momenta’s pipeline, led by a potential drug for anemia.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|